Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

LEASES (Tables)

9 Months Ended

Sep. 30, 2022

The components of our operating lease expense were as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Fixed operating lease expense	$	1,340	$	1,340	$	4,020	$	4,020
Variable operating lease expense		211		259		602		651
Total operating lease expense	$	1,551	$	1,599	$	4,622	$	4,671

Supplemental information related to our operating lease were as follow (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Cash payments included in the measurement of operating lease liabilities	$	2,630	$	2,529	$	7,856	$	7,554

Supplemental information related to our operating sublease was as follow (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Fixed sublease expense	$	1,095	$	1,095	$	3,285	$	3,285
Variable sublease expense		232		236		682		680
Sublease income		(1,327)		(1,331)		(3,967)		(3,965)
Net	$	—	$	—	$	—	$	—

The following table presents the future lease payments of our operating lease liabilities as of September 30, 2022 (in thousands):


		Operating Lease		Sublease Receipts		Net
Remainder of 2022	$	2,630		(1,183)		1,447
2023		877		(394)		483
Total minimum payments required	$	3,507	$	(1,577)	$	1,930